top of page
Topic: Digestive rare cancers
CPGs graded Strong
Martin-Richard M, Beveridge RD et al. (2016). SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer. DOI 10.1007/s12094-016-1577-y; Clin Transl Oncol (2016) 18:1179–1186. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5138258/pdf/12094_2016_Article_1577.pdf
​
Moureau-Zabotto L, Vendrely V et al. (2017). Anal cancer: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SNFCP). Digestive and Liver Disease 49 (2017) 831–840. https://www.dldjournalonline.com/article/S1590-8658(17)30888-5/pdf
​
Porschen R, Buck A, Fischbach W et al. (2015). S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus (Langversion 1.0 - September 2015, AWMFRegisternummer: 021/023OL). (Squamous cell carcinoma of esophagus). https://www.leitlinienprogramm-onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Oesophaguskarzinom/LL_Oesophagus_Langversion_1.0.pdf
​
Marchal F et al. (oncologik). Adénocarcinome de l'œsophage et de la jonction œsogastrique. 
http://oncologik.fr/telecharger-pdf/adenocarcinome-de-l-oesophage-et-de-la-jonction-oesogastrique
​
Giani, I., Mistrangelo, M et al. (2013). The treatment of squamous anal carcinoma: guidelines of the Italian society of colo-rectal surgery. DOI: https://doi.org/10.1007/s10151-012-0912-8; 
https://link.springer.com/article/10.1007%2Fs10151-012-0912-8
​
Luporini AG, Astli E, Bidoili P et al. (2017). Linee guida Tumori dell'esofago. Associazione Italiana di Oncologia Medica (AIOM)/ Guidelines for esophageal tumours. http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Esofago.pdf
​
Aschele C, Pastorino A, Messina M et al. Linee guida Neoplasie del Retto e Ano (Guidelines rectal and anal cancers); 
http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Retto.pdf
​
Stahl M, Mariette C, Haustermans K et al. (2013). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 24 (Supplement 6): vi51–vi56, 2013 doi:10.1093/annonc/mdt342. 
https://academic.oup.com/annonc/article-pdf/27/suppl_5/v50/6679311/mdw329.pdf
​
Glynne-Jones R., Nilsson P.J., Aschele C. et al. (2014). Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. DOI: https://doi.org/10.1016/j.radonc.2014.04.013; Radiotherapy and Oncology, 111 (3), pp. 330-339. https://academic.oup.com/annonc/article-pdf/25/suppl_3/iii10/6674996/mdu159.pdf
​
Bridgewater JGalle PRKhan SA et al. (2014). Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014 Jun;60(6):1268-89. doi: 10.1016/j.jhep.2014.01.021. DOI: 10.1016/j.jhep.2014.01.021; 
https://www.journal-of-hepatology.eu/article/S0168-8278(14)00067-1/pdf
​
Valle, J. W., et al. (2016). Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 27(suppl_5): v28-v37. https://academic.oup.com/annonc/article-pdf/27/suppl_5/v28/6678340/mdw324.pdf
CPGs graded Moderate
Tonini G, Pantano F, Brandi G et al. Linee guida Tumori delle vie biliari. Associazione Italiana di Oncologia Medica (AIOM) / Guidelines for biliary tract cancers.http://media.aiom.it/userfiles/files/doc/LG/2017_LGAIOM_Vie_biliari.pdf
​
Benavides M., Antón A., Gallego J et al. (2015). Biliary tract cancers: SEOM clinical guidelines. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 17(12), 982–987. doi:10.1007/s12094-015-1436-2; Clin Transl Oncol (2015) 17:982–987.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689747/pdf/12094_2015_Article_1436.pdf
​
Lordick FMariette CHaustermans K et al. (2016). Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v50-v57. https://academic.oup.com/annonc/article-pdf/27/suppl_5/v50/6679311/mdw329.pdf
​
Kluijt ISijmons RHHoogerbrugge N et al. (2012). Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 11(3), 363-369. https://doi.org/10.1007/s10689-012-9521-y. DOI:10.1007/s10689-012-9521-y; 
https://www.rug.nl/research/portal/files/6786717/Kluijt_2012_Fam_Cancer.pdf
​

Khan SA, Davidson BR, Goldin RD, et al. (2012). Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update

Gut 2012;61:1657-1669; Doi: 10.1136/gutjnl-2011-301748. https://gut.bmj.com/content/gutjnl/61/12/1657.full.pdf

​
Satvinder Mudan: LCA Hepato-pancreatobiliary Cancer Clinical Guidelines. London Cancer Alliance 2014; 
http://www.londoncanceralliance.nhs.uk/media/87762/lca-hpb-cancer-clinical-guidelines-november-2014.pdf
​
Malka D, Chiche L, Baere T, Dromain C et al. (2014). Thésaurus national de cancérologie digestive: Cancer des voies biliaires; https://www.snfge.org/sites/default/files/recommandations/tncd_chap-8-cancer-voies-biliaires_2014-01-24.pdf
Unbenannt.JPG

Work Package 6

_project_management_standards.jpg

Tasks of work package 6

​

  • Map available clinical practice guidelines (CPGs) at the European level on all families of rare cancers and identify gaps

  • Quality evaluation of existing guidelines for rare cancer subtypes  

​

The JARC Work Package 6 maintains this website to share the results of quality evaluation of existing CPGs at European local and national level on rare cancers with partners involved in the EU JARC Project. However, the JARC Work Package 6 does not accept any responsibility or obligation of any kind whatsoever with regard to the information contained on this site.

The  JARC WP 6 Website contains links to other websites.

Not having control over the content of these third-party websites, no responsibility is assumed for their policies or practices.

Therefore, please review the privacy policies of these third-party websites.

Tasks of work package 6

​​

  • Open issues about implementation of CPGs at the local level and their interface with reimbursement systems

  • Work out solutions on how to assess the implementation of CPGs in the context of ERNs and national clinical collaborative networks

bottom of page